Literature DB >> 21781972

Rapid assessment of in vitro expanded human regulatory T cell function.

Joyce J Ruitenberg1, Christopher Boyce, Ravi Hingorani, Amy Putnam, Smita A Ghanekar.   

Abstract

Human regulatory T cells (Treg) are able to actively suppress autoreactive immune responses. Phenotypically, they are broadly characterized as CD4+, CD25+, CD127(lo/⁻) and FoxP3+. CD45RA can be used to further differentiate the population into naïve (CD45RA(+)) and induced (CD45RA⁻) Treg. The functional potential of Treg is routinely determined by assessing their ability to suppress T cell function in 3-5day proliferation assays. Since Treg are being explored for therapeutic use, a short-term functional assay could serve as a valuable tool for evaluating the potency of Treg. Therefore, an assay designed to measure Treg suppression of activation marker expression by responder T cells in 7 to 20h has been examined in this report. Using flow cytometry, expression of CD69 and CD154 on T cells, in response to stimulation with CD3/CD28 beads, was used as a measure of activation in the assay. Treg from healthy volunteers were sorted as CD4+CD25+CD127(lo/⁻)CD45RA+ cells with a BD FACSAria™ II. The highly purified Treg were then expanded in vitro and their function was assessed in short term activation marker suppression assays using autologous PBMC as responder cells. The data suggest that this short term suppression assay could be a reliable surrogate for assessing Treg functional potential.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21781972     DOI: 10.1016/j.jim.2011.07.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

1.  Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Authors:  Bahey Salem; Samantha Miner; Nancy F Hensel; Minoo Battiwalla; Keyvan Keyvanfar; David F Stroncek; Adrian P Gee; Patrick J Hanley; Catherine M Bollard; Sawa Ito; A John Barrett
Journal:  Cytotherapy       Date:  2015-09-28       Impact factor: 5.414

2.  Isolation of biologically-active exosomes from human plasma.

Authors:  Laurent Muller; Chang-Sook Hong; Donna B Stolz; Simon C Watkins; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2014-06-18       Impact factor: 2.303

3.  Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Authors:  Emma M Haapaniemi; Meri Kaustio; Hanna L M Rajala; Arjan J van Adrichem; Leena Kainulainen; Virpi Glumoff; Rainer Doffinger; Heikki Kuusanmäki; Tarja Heiskanen-Kosma; Luca Trotta; Samuel Chiang; Petri Kulmala; Samuli Eldfors; Riku Katainen; Sanna Siitonen; Marja-Liisa Karjalainen-Lindsberg; Panu E Kovanen; Timo Otonkoski; Kimmo Porkka; Kaarina Heiskanen; Arno Hänninen; Yenan T Bryceson; Raija Uusitalo-Seppälä; Janna Saarela; Mikko Seppänen; Satu Mustjoki; Juha Kere
Journal:  Blood       Date:  2014-10-27       Impact factor: 22.113

4.  Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways.

Authors:  N A Zwang; R Zhang; S Germana; M Y Fan; W D Hastings; A Cao; L A Turka
Journal:  Am J Transplant       Date:  2016-05-23       Impact factor: 8.086

5.  Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.

Authors:  Theresa L Whiteside
Journal:  Cancer Microenviron       Date:  2014-11-12

Review 6.  Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.

Authors:  Nicholas A Zwang; Joseph R Leventhal
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

7.  A novel and rapid method to quantify Treg mediated suppression of CD4 T cells.

Authors:  Anna E Long; Megan Tatum; Carmen Mikacenic; Jane H Buckner
Journal:  J Immunol Methods       Date:  2017-06-22       Impact factor: 2.303

Review 8.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

9.  Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.

Authors:  Radu Tanasescu; Christopher R Tench; Cris S Constantinescu; Gary Telford; Sonika Singh; Nanci Frakich; David Onion; Dorothee P Auer; Bruno Gran; Nikos Evangelou; Yasser Falah; Colin Ranshaw; Cinzia Cantacessi; Timothy P Jenkins; David I Pritchard
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

10.  Differential Roles of IL-2 Signaling in Developing versus Mature Tregs.

Authors:  Martin Y Fan; Jun Siong Low; Naoki Tanimine; Kelsey K Finn; Bhavana Priyadharshini; Sharon K Germana; Susan M Kaech; Laurence A Turka
Journal:  Cell Rep       Date:  2018-10-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.